A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
NCT06024746
This study is recruiting at 46 US sites in 20 states, according to its ClinicalTrials.gov record last updated .
Summary
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Heart Failure
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Colorado Prevention Center
- Last updated on ClinicalTrials.gov
- September 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- CON-10004 Fairhope, AL Investigational Site · Fairhope, AL
Arizona · 1
- Phoenix, AZ Investigative Site CON-10115 · Phoenix, AZ
California · 6
- Chula Vista, CA Investigative Site CON-10111 · Chula Vista, CA
- CON-10075 El Centro, CA Investigational Site · El Centro, CA
- CON-10024 Sacramento, CA Investigational Site · Sacramento, CA
- CON-10023, San Francisco, CA · San Francisco, CA
- San Francisco, CA Investigative Site CON-10315 · San Francisco, CA
- CON-10109, Van Nuys, CA · Van Nuys, CA
Colorado · 2
- CON-10001, Aurora, CO · Aurora, CO
- CON-10005, Denver, CO · Denver, CO
Florida · 5
- Bradenton, FL Investigative Site CON-10125 · Bradenton, FL
- Fort Lauderdale, FL Investigative Site CON-10114 · Fort Lauderdale, FL
- CON-10078, Hialeah, FL · Hialeah, FL
- CON-10105, Miami, FL · Miami, FL
- CON-10113, Miramar, FL · Miramar, FL
Georgia · 1
- CON-10022 Atlanta, GA Investigational Site · Atlanta, GA
Illinois · 4
- CON-10021, Glenview, IL · Glenview, IL
- CON-10041, Island Lake, IL · Island Lake, IL
- CON-10025, Naperville, IL · Naperville, IL
- CON-10019, Peoria, IL · Peoria, IL
Indiana · 1
- CON-10064, Merrillville, IN · Merrillville, IN
Kentucky · 4
- CON-10080, Lexington, KY · Lexington, KY
- Lexington, KY Investigative Site CON-10118 · Lexington, KY
- CON-10086, Louisville, Kentucky · Louisville, KY
- CON-10079, Paducah, KY · Paducah, KY
Louisiana · 2
- CON-10030 Baton Rouge, LA Investigational Site · Baton Rouge, LA
- CON-10090, West Monroe, LA · West Monroe, LA
Minnesota · 1
- Minneapolis, MN Investigative Site CON-10035 · Minneapolis, MN
Missouri · 1
- CON-10002 Kansas City, MO Investigative Site · Kansas City, MO
Nebraska · 1
- CON-10018, Omaha, NE · Omaha, NE
North Carolina · 3
- CON-10318, Charlotte, NC · Charlotte, NC
- Greenville, NC Investigative Site CON-10122 · Greenville, NC
- Morrisville, NC Investigative Site CON-10317 · Morrisville, NC
Ohio · 1
- CON-10119, Centerville, OH · Centerville, OH
Pennsylvania · 1
- Philadelphia, PA Investigative Site CON-10068 · Philadelphia, PA
Tennessee · 1
- CON-10051, Chattanooga, TN · Chattanooga, TN
Texas · 7
- CON-10045 Amarillo, TX Investigational Site · Amarillo, TX
- CON-10015 Austin, TX Investigational Site · Austin, TX
- CON-10304, Denison, TX · Denison, TX
- CON-10301, Fort Worth, TX · Fort Worth, TX
- CON-10085, Houston, TX · Houston, TX
- Houston, TX Investigative Site CON-10320 · Houston, TX
- Texarkana, TX Investigative Site CON-10319 · Texarkana, TX
Utah · 1
- CON-10305, Layton, UT · Layton, UT
Virginia · 2
- CON-10009, Norfolk, VA · Norfolk, VA
- Salem, VA Investigative Site CON-10048 · Salem, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.